Analyst Thinks Johnson & Johnson Could Hit a $280 Target
A major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Zero-based budgeting often brings discipline and clarity, but users may face tracking fatigue and adjustment pains that need strategies.
16,635 articlesA major analyst raises the price target on Johnson & Johnson to $280, arguing growing oncology sales and a planned sp...
Two tobacco giants show divergent paths over 10 years, with dividend income boosting returns for both. Here's what ha...
A cultural meme is shaping money decisions in licensing, estate planning, and brand strategy. Here’s how chuck norris...
A NOVA-based startup is turning years of real‑world chaos into hours of simulated mayhem to stress‑test critical syst...
When a streaming giant passes on a blockbuster deal, it sends a clear message about prioritizing value over hype. Thi...
As Rex gears up to report Q4 2025 results, investors should focus on growth drivers, margins, and the outlook. This g...
Nuclear energy stocks are poised for renewed interest in 2026 thanks to reliability, carbon-free power, and policy ta...
Peloton posted a GAAP profit in its latest quarter and raised full-year guidance, sparking an 11% premarket jump as i...
How did xplr (xifr) perform in Q1 2026, and what does it mean for 2026 earnings guidance? This article breaks down th...
Eight senior executives have left Canoo in a fresh churn while the EV maker fights to meet long-running production ta...
QuantumScape stock rallies on the Eagle Line milestone and early customer billings, signaling a shift from research t...
A Valvoline executive explains how the company backs young workers through mentorship, fair pay, and career paths ami...